These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23683309)

  • 41. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.
    Lai R; Katalinic N; Glue P; Somogyi AA; Mitchell PB; Leyden J; Harper S; Loo CK
    World J Biol Psychiatry; 2014 Sep; 15(7):579-84. PubMed ID: 24910102
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2014; 48(1):49-58. PubMed ID: 24946434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.
    Albott CS; Shiroma PR; Cullen KR; Johns B; Thuras P; Wels J; Lim KO
    J Clin Psychiatry; 2017 Mar; 78(3):e308-e309. PubMed ID: 28394513
    [No Abstract]   [Full Text] [Related]  

  • 45. Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression: acute versus long-term data.
    Dell'Osso B; Ketter TA
    Int Clin Psychopharmacol; 2013 Nov; 28(6):297-304. PubMed ID: 24081199
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined antidepressant treatment: a risk factor for switching in bipolar patients.
    Gabbay V; O'Dowd MA; Asnis GM
    J Clin Psychiatry; 2002 Apr; 63(4):367; author reply 367-8. PubMed ID: 12000212
    [No Abstract]   [Full Text] [Related]  

  • 47. Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review.
    Veraart JKE; Smith-Apeldoorn SY; Spijker J; Kamphuis J; Schoevers RA
    J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34255943
    [No Abstract]   [Full Text] [Related]  

  • 48. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
    van Schalkwyk GI; Wilkinson ST; Davidson L; Silverman WK; Sanacora G
    J Affect Disord; 2018 Feb; 227():11-16. PubMed ID: 29045915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.
    Singh B; Bobo WV; Rasmussen KG; Stoppel CJ; Rico JA; Schak KM; Biernacka JM; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2019 Nov; 80(6):. PubMed ID: 31721482
    [No Abstract]   [Full Text] [Related]  

  • 50. Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: two case reports.
    Serra G; De Chiara L; Koukopoulos A; Serra G
    J Clin Psychopharmacol; 2013 Oct; 33(5):715-7. PubMed ID: 24002206
    [No Abstract]   [Full Text] [Related]  

  • 51. [Practical aspects of ketamine treatment-Safety, combination treatment and comorbidities].
    Findeis H; Ludwig V; Mikolas P; Graff J; Bauer M; Ritter P
    Nervenarzt; 2022 Mar; 93(3):243-253. PubMed ID: 35171310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can we confidently use ketamine as a clinical treatment for depression?
    Loo C
    Lancet Psychiatry; 2018 Jan; 5(1):11-12. PubMed ID: 29277196
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy and safety of ketamine in bipolar depression: A systematic review.
    Alberich S; Martínez-Cengotitabengoa M; López P; Zorrilla I; Núñez N; Vieta E; González-Pinto A
    Rev Psiquiatr Salud Ment; 2017; 10(2):104-112. PubMed ID: 27387226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Ketamine as antidepressant: the current study situation].
    Ritter PS; Bauer M; Pilhatsch M
    Nervenarzt; 2014 Nov; 85(11):1432-5. PubMed ID: 25324145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
    Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
    J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and "depressed" mice exposed to chronic mild stress.
    Franceschelli A; Sens J; Herchick S; Thelen C; Pitychoutis PM
    Neuroscience; 2015 Apr; 290():49-60. PubMed ID: 25595985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urothelial toxicity of esketamine in the treatment of depression.
    Findeis H; Sauer C; Cleare A; Bauer M; Ritter P
    Psychopharmacology (Berl); 2020 Nov; 237(11):3295-3302. PubMed ID: 32712681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alternative approaches to refractory depression in bipolar illness.
    Post RM; Leverich GS; Denicoff KD; Frye MA; Kimbrell TA; Dunn R
    Depress Anxiety; 1997; 5(4):175-89. PubMed ID: 9338110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Transition from the depressive stage to the manic stage during the treatment with antidepressive drugs].
    Koszewska I; Puzyński S
    Psychiatr Pol; 1991; 25(3-4):76-82. PubMed ID: 1821982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
    Liebrenz M; Stohler R; Borgeat A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.